<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Arbuck, S.</style></author><author><style face="normal" font="default" size="100%">Huber, M.</style></author><author><style face="normal" font="default" size="100%">Weber, D.</style></author><author><style face="normal" font="default" size="100%">Luckett, R.</style></author><author><style face="normal" font="default" size="100%">Delasalle, K.</style></author><author><style face="normal" font="default" size="100%">Alexanian, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Primary therapy of multiple myeloma with paclitaxel (taxol)</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Paclitaxel</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1994</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028064597&amp;partnerID=40&amp;md5=f796674e1e73f4ae86feb6ad469cb05f</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">757 - 759</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: The treatment of multiple myeloma remains unsatisfactory and new active agents are needed. Paclitaxel is effective against a variety of solid tumors and we assessed the utility against multiple myeloma. Patients and methods: From March 1993 to May 1994, we treated 33 patients with newly diagnosed multiple myeloma with paclitaxel given intravenously at a dose of 125 mg/m2 over 24 hours (13 patients) or at a dose of 135 mg/m2 over 3 hours (20 patients). Results: Five of 33 patients responded (15%; 95% CI: 5 to 32%) with an unmaintained remission of 3-11+ months. Severe but reversible neutropenia was the major dose limiting toxicity, but myalgias and alopecia were also common. Conclusions: Paclitaxel was slightly active against multiple myeloma. Whether higher doses or new analogues of this agent can produce superior results requires further study. © 1994 Kluwer Academic Publishers.</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><notes><style face="normal" font="default" size="100%">Cited By :18Export Date: 21 February 2017</style></notes></record></records></xml>